Examiner: MELCHIOR, JAMES RYLAND

Tech Center 1600 • Art Units: 1644 1658

This examiner grants 63% of resolved cases

Performance Statistics

62.7%

Allow Rate

+2.7% vs TC avg

Total Applications

+37.7%

Interview Lift

1310

Avg Prosecution Days

Based on 67 resolved cases, 2023–2026

2.1%

§101 Eligibility

13.4%

§102 Novelty

29.5%

§103 Obviousness

29.0%

§112 Clarity

App #	Title	Status	Assignee
18363155	Multispecific Binding Protein Degrader Platform and Methods of Use	Non-Final OA	Genentech Inc.
18302636	COMBINATIONAL IMMUNOTHERAPIES USING CAR-M, CAR-NK, CAR-EOS, AND CAR-N CELLS	Non-Final OA	Wisconsin Alumni Research Foundation
18248205	BISPECIFIC ANTIBODY TREATMENT OF LYMPHOID MALIGNANT NEOPLASM CONDITIONS	Non-Final OA	CELGENE CORPORATION
18162344	BISPECIFIC ANTIBODY THERAPIES	Final Rejection	CytoAgents, Inc.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.